 - For dose escalation subject must have histologically andor cytologically documented cancer for which etoposidecisplatin has been determined to be an appropriate therapy. For expanded safety cohort subject must have histologically andor cytologically documented SCLC for which etoposidecisplatin has been determined an appropriate therapy; 